CervoMed Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRVO Nasdaq 2834 www.cervomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CervoMed Inc.

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - Jun 10th, 2025 6:00 am
CervoMed First Quarter 2025 Earnings: Beats Expectations - May 14th, 2025 5:27 am
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2025 7:15 am
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - May 12th, 2025 6:00 am
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference - May 7th, 2025 6:00 am
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 - Apr 2nd, 2025 5:00 am
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) - Mar 25th, 2025 6:00 am
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Mar 19th, 2025 2:27 pm
CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 18th, 2025 4:41 am
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now - Mar 18th, 2025 2:48 am
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates - Mar 17th, 2025 6:00 am
Why CervoMed Inc. (CRVO) Soared Last Week? - Mar 17th, 2025 5:28 am
CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program - Mar 14th, 2025 9:25 am
We Think CervoMed (NASDAQ:CRVO) Can Afford To Drive Business Growth - Mar 14th, 2025 4:30 am
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - Mar 10th, 2025 2:05 pm
Why CervoMed (CRVO) Is Advancing Today - Feb 19th, 2025 12:09 pm
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference - Jan 31st, 2025 6:00 am
CervoMed to Present at the 8th International Lewy Body Dementia Conference - Jan 29th, 2025 6:00 am
CervoMed price target lowered to $4 from $45 at Roth MKM - Dec 12th, 2024 5:45 am
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 12th, 2024 5:00 am